載入中
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
前收盤價
US$1.12
+US$0.03 · +2.75%
盤中時間採用ET。市場資料可能有所延遲。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日內區間
目前US$1.12
52週區間
目前US$1.12
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
57
多空交錯
風險
82
極高風險
動能
16
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日內區間
目前US$1.12
52週區間
目前US$1.12
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 62.25萬 USD | 391.52萬 USD | 681.2萬 USD | 3421.82萬 USD | 9788.56萬 USD |
| 銷貨成本 | 22.24萬 USD | 99.91萬 USD | 418.49萬 USD | 548.11萬 USD | 1157.49萬 USD |
| 毛利 | 40.01萬 USD | 291.6萬 USD | 262.71萬 USD | 2873.71萬 USD | 8631.07萬 USD |
| 研究與開發 | 1913.72萬 USD | 2097.96萬 USD | 2296.26萬 USD | 1743.81萬 USD | 1496.19萬 USD |
| 銷售、一般及管理費用 | 1143.94萬 USD | 2064.05萬 USD | 2114.03萬 USD | 2160.76萬 USD | 2494.84萬 USD |
| 營業費用 | 3168.35萬 USD | 4299.73萬 USD | 4533.33萬 USD | 5571.7萬 USD | 4024.57萬 USD |
| 利息收入 | 29.29萬 USD | 109.18萬 USD | 116.19萬 USD | 70.4萬 USD | 4.56萬 USD |
| 折舊和攤銷 | 110.68萬 USD | 137.73萬 USD | 123.05萬 USD | 128.27萬 USD | 33.54萬 USD |
| 營業利益 | −3128.34萬 USD | −4008.13萬 USD | −4270.62萬 USD | −2697.98萬 USD | 4606.5萬 USD |
| 淨利 | −4689.59萬 USD | −3763.9萬 USD | −3533.29萬 USD | −1423.82萬 USD | 3665.86萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
